Assessing the effectiveness of oxybutynin and phenazopyridine and celecoxib in reducing complications in the treatment of bladder tumors.

Comparison of the efficacy of oxybutynin and phenazopyridine and celecoxib with placebo in the treatment of urinary tract symptoms after BCG therapy in bladder tumors patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171225038070N1

Enrollment

120

Registered

2018-07-08

Start date

2016-07-05

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of bladder. Malignant neoplasm of bladder

Interventions

Intervention 1: Intervention group1: Receive oxybutinine 5 mg every 12 hours for six weeks BCG treatment. Intervention 2: Intervention group2: phenazopyridine 100 mg every 8 hours for six weeks BCG tr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: bladder cancer candidates for BCG therapy Non muscle bladder cancer

Exclusion criteria

Exclusion criteria: history of pelvic surgery severe urinary tract symptoms (IPSS over 20) overactive bladder complete urinary incontinence traumatic catheterization active TB symptoms

Design outcomes

Primary

Measure	Time frame
Frequency. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.	—

Secondary

Measure	Time frame
Urgency. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Urine painful. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Fever. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Thermometer.;Constipation. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Heart burn. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Feeling dry mouth. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Flu-like symptoms. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Arthralgia. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.	—

Measure

Time frame

Urgency. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Urine painful. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Fever. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Thermometer.;Constipation. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Heart burn. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Feeling dry mouth. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Flu-like symptoms. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.;Arthralgia. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Nikbakht

Iran University of Medical Sciences

javad.nikbakht64@gmail.com+98 21 8864 4435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026